Table 2.

Pooled adverse events in registration trials of CDK4/6 inhibitors in combination with an aromatase inhibitor as first-line treatment in hormone receptor-positive, HER2-negative breast cancer patients [8]

	Age < 65 years N = 625 (%)	Age ≥ 65 years N = 479 (%)	Age ≥ 70 years N = 280 (%)
AE leading to dose reduction and/or interruption	411 (66)	360 (75)	216 (77)
AE leading to discontinuation	50 (8)	76 (16)	48 (17)
Grade 1–2 AEs	610 (98)	470 (98)	277 (99)
Grade 3–4 AEs	417 (66)	385 (80)	229 (82)
Grade 5 AEs	7 (1)	11 (2)	8 (3)
Serious AEs	103 (16)	147 (31)	93 (33)

AE adverse events